ATE235058T1 - Screening von wirkstoffen zur behandlung von alzheimer-krankheit - Google Patents
Screening von wirkstoffen zur behandlung von alzheimer-krankheitInfo
- Publication number
- ATE235058T1 ATE235058T1 AT97923188T AT97923188T ATE235058T1 AT E235058 T1 ATE235058 T1 AT E235058T1 AT 97923188 T AT97923188 T AT 97923188T AT 97923188 T AT97923188 T AT 97923188T AT E235058 T1 ATE235058 T1 AT E235058T1
- Authority
- AT
- Austria
- Prior art keywords
- agent
- alzheimer
- disease
- filaments
- treatment
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 4
- 238000012216 screening Methods 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 102000013498 tau Proteins Human genes 0.000 abstract 2
- 108010026424 tau Proteins Proteins 0.000 abstract 2
- 229920002683 Glycosaminoglycan Polymers 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 238000011835 investigation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 229920001307 poly(hydroxymethylethylene hydroxymethyl formal) Polymers 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
- Y10T436/144444—Glucose
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9610829.5A GB9610829D0 (en) | 1996-05-23 | 1996-05-23 | Screening of agents for treatment of azlheimers disease |
| PCT/GB1997/001356 WO1997044669A1 (en) | 1996-05-23 | 1997-05-20 | Screening of agents for treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE235058T1 true ATE235058T1 (de) | 2003-04-15 |
Family
ID=10794213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97923188T ATE235058T1 (de) | 1996-05-23 | 1997-05-20 | Screening von wirkstoffen zur behandlung von alzheimer-krankheit |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6245575B1 (de) |
| EP (1) | EP0901633B1 (de) |
| JP (1) | JP2001503509A (de) |
| AT (1) | ATE235058T1 (de) |
| DE (1) | DE69719978T2 (de) |
| DK (1) | DK0901633T3 (de) |
| ES (1) | ES2194198T3 (de) |
| GB (1) | GB9610829D0 (de) |
| PT (1) | PT901633E (de) |
| WO (1) | WO1997044669A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998025640A2 (en) * | 1996-12-13 | 1998-06-18 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel methods for testing inhibitors of paired helical filaments and uses for treatment of alzheimer's disease |
| CA2504035A1 (en) * | 2002-11-01 | 2004-05-21 | Proteotech, Inc. | Amyloid plaque formation by glycosaminoglycans |
| FR2888937B1 (fr) * | 2005-07-21 | 2012-10-26 | Biomerieux Sa | Procede de detection des fcpa utilisant un agent d'agregation des fcpa et un agent de capture des agregats formes |
| KR101095630B1 (ko) * | 2009-06-17 | 2011-12-19 | 주식회사 이노파마스크린 | 베타 아밀로이드 펩타이드와 ｖｅｇｆ의 상호작용을 억제하는 물질을 탐색 방법 및 그에 의해서 탐색된 저해제 |
| JP2013032295A (ja) * | 2009-12-04 | 2013-02-14 | Kaneka Corp | タウ蛋白の吸着材および吸着除去システム |
| EP3602046A1 (de) * | 2017-03-28 | 2020-02-05 | Janssen Vaccines & Prevention B.V. | Verfahren zum nachweis von tau-proteinaggregationsmodulierenden verbindungen |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5164295A (en) * | 1991-03-06 | 1992-11-17 | The Upjohn Company | Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds |
| DE69227380T3 (de) | 1991-11-12 | 2007-01-11 | Prana Biotechnology Ltd., South Melbourne | Verfahren zur bestimmung und behandlung von alzheimer-krankheit |
| WO1993011231A1 (en) | 1991-12-06 | 1993-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tools for the diagnosis and treatment of alzheimer's disease |
| US5643562A (en) * | 1993-03-29 | 1997-07-01 | Queen's University Of Kingston | Method for treating amyloidosis |
| US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
-
1996
- 1996-05-23 GB GBGB9610829.5A patent/GB9610829D0/en active Pending
-
1997
- 1997-05-20 JP JP54178697A patent/JP2001503509A/ja not_active Ceased
- 1997-05-20 ES ES97923188T patent/ES2194198T3/es not_active Expired - Lifetime
- 1997-05-20 AT AT97923188T patent/ATE235058T1/de not_active IP Right Cessation
- 1997-05-20 WO PCT/GB1997/001356 patent/WO1997044669A1/en not_active Ceased
- 1997-05-20 EP EP97923188A patent/EP0901633B1/de not_active Expired - Lifetime
- 1997-05-20 US US09/194,127 patent/US6245575B1/en not_active Expired - Fee Related
- 1997-05-20 DK DK97923188T patent/DK0901633T3/da active
- 1997-05-20 DE DE69719978T patent/DE69719978T2/de not_active Expired - Fee Related
- 1997-05-20 PT PT97923188T patent/PT901633E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997044669A1 (en) | 1997-11-27 |
| EP0901633A1 (de) | 1999-03-17 |
| DK0901633T3 (da) | 2003-06-16 |
| JP2001503509A (ja) | 2001-03-13 |
| ES2194198T3 (es) | 2003-11-16 |
| EP0901633B1 (de) | 2003-03-19 |
| GB9610829D0 (en) | 1996-07-31 |
| DE69719978T2 (de) | 2003-12-18 |
| US6245575B1 (en) | 2001-06-12 |
| PT901633E (pt) | 2003-07-31 |
| DE69719978D1 (de) | 2003-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69533040D1 (de) | Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien | |
| DE69822665D1 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
| ATE131068T1 (de) | Behandlung von pathologischen zuständen und krankheiten. | |
| ATE330631T1 (de) | Antikörperfragmente zur lokalen behandlung von augenerkrankungen | |
| RU94042387A (ru) | Композиция для лечения ран и фиброзных заболеваний, способ получения композиции, способ лечения ран и фиброзных заболеваний | |
| DE60045550D1 (de) | Vorbeugung und behandlung von amyloidogenischen krankheiten | |
| DE69429527D1 (de) | Inhibitoren von beta-amyloid-protein-herstellung | |
| BR9909382A (pt) | Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado | |
| ATE214924T1 (de) | Verwendung von nebivolol als anti-atherogenisches mittel | |
| DE69432299D1 (de) | Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen | |
| ATE327764T1 (de) | Hmg1 antagonisten zur behandlung von entzündungen | |
| DE69527847D1 (de) | Verwendung von anti-vegf-mitteln zur behandlung der endometriose | |
| DE69631478D1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
| EA200301253A1 (ru) | Применение остеопонтина для лечения и/или профилактики неврологических заболеваний | |
| GR1000611B (el) | Μεθοδος για την παρασκευη οφθαλμικων συνθεσεων κυκλοσπορινης. | |
| ATE201992T1 (de) | Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen | |
| DE69531004D1 (de) | p277 PEPTIDANALOGE, PHARMAZEUTISCHE ZUSAMMENSTELLUNG DAVON ZUR BEHANDLUNG UND DIAGNOSE VON DIABETES | |
| DE69711078D1 (de) | Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz | |
| ATE196083T1 (de) | Verwendung von ferrioxamin-b zur behandlung septischen schocks | |
| DE69719978D1 (de) | Screening von wirkstoffen zur behandlung von alzheimer-krankheit | |
| JO3446B1 (ar) | طريقة لمعالجة الأرق الأولي | |
| ATE293994T1 (de) | Multivalente rekombinante antikörper zur behandlung von hrv infektionen | |
| DE69014501D1 (de) | Verfahren zur Behandlung von Titanlegierung und damit hergestelltes Stück. | |
| NO984651D0 (no) | Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet | |
| ATE249832T1 (de) | Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0901633 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |